ClinicalTrials.gg
RecruitingNCT05556460Updated Jun 12, 2026

Safety and Effectiveness Study of DragonFly-T System for Severe Tricuspid Regurgitation

An interventional study of DragonFly-T Transcatheter Tricuspid Valve Repair System and Medical therapy in Tricuspid Regurgitation, sponsored by Hangzhou Valgen Medtech Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Hangzhou Valgen Medtech Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Tricuspid Valve Insufficiency with a site in China — 19 open to participants now, 21 under way, none of them phase 3. Tricuspid Valve Insufficiency · China.

Planned enrollment
4th of 16
236 · median 129
Started
2024
with 5 others
No phase
15 of 28
9 open now
Primary completion
2028-08
later than 15 of 20 live
Registered
10th of 28
by date
Lead sponsor
3 of 28
Hangzhou Valgen Medtech Co., Ltd

Among the 28 studies in Tricuspid Valve Insufficiency with a site in China, this one is the 4th largest by planned enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2024, is one of 15 with no phase, reaches primary completion later than 15 of the 20 other live ones, and was the 10th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

19 of the 28 studies in Tricuspid Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Tricuspid Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

The primary objective of this trial is to demonstrate the safety and effectiveness of the DragonFly-T system in improving clinical outcomes in symptomatic patients with severe tricuspid regurgitation (TR), who are at intermediate or greater estimated risk for mortality or morbidity with tricuspid valve surgery. This randomized controlled trial will compare the investigational device (DragonFly-T system) to Control (Medical Therapy).

Read the detailed description

A Prospective, Multicenter, Parallel, Randomized Controlled Study to Evaluate the Safety and Efficacy of the DragonFly-T Transcatheter Tricuspid Valve Clip System in the Treatment of Tricuspid Regurgitation. After signing the informed consent form, participants in the experimental group will be treated with the Dejin Medical DragonFly-T Transcatheter Tricuspid Valve Clip System and continue receiving medical therapy as determined by the investigator. Participants in the control group will continue to receive medical therapy as determined by the investigator. Control group participants are allowed to cross over to the experimental group after completing the 12-month follow-up. All participants will undergo clinical follow-up before discharge (not applicable to control group participants), at 30 days post-treatment, 6 months post-treatment, 12 months post-treatment, and annually at 2, 3, 4, and 5 years..

The primary endpoint is the hierarchical composite endpoint formed by all-cause mortality or tricuspid valve reintervention, heart failure hospitalization, and KCCQ improvement at 12 months post-treatment.

To evaluate the safety and effectiveness of the Valgen Medtech DragonFly-T Transcatheter Tricuspid Valve Repair System in the treatment of patients with severe tricuspid regurgitation (TR), who are at intermediate or greater estimated risk for mortality or morbidity with tricuspid valve surgery.

03

Conditions studied

  • Tricuspid Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. In the judgment of the local cardiac team, the patient has been adequately treated according to applicable standards (including medical management)and has been stable for at least 30 days.
  3. Despite the drug optimization treatment according to the above method, patients still have symptoms of TR;
  4. Determined by the local cardiac team to be at intermediate or higher risk for tricuspid valve surgery
  5. (NYHA) Cardiac function Class II-IVa;

5. The patient is suitable for transcatheter tricuspid valve repair, suitable for the use of this study instrument, and the femoral vein access is feasible and can accommodate catheter; 6. Patient must provide written before any steps related to the study.

Exclusion criteria

Exclusion Criteria:

  1. Tricuspid valve leaflet anatomy, which may preclude clip implantation, proper clip positioning on the leaflets, including but not limited to the following:

    1. Evidence of calcification in the grasping area;
    2. Presence of a severe coaptation defect of the tricuspid leaflets;
    3. Severe leaflet defect(s) and cleft preventing proper device placement determined by ECL;
    4. Epstein anomaly.
  2. Other serious heart valvular diseases requiring intervention or planning to intervention in the next 12 months; Note: If mitral and tricuspid valve lesions are combined, mitral valve surgery can be performed first, and re-evaluation can be performed 60 days after surgery.
  3. Tricuspid stenosis evaluated by ECL and/or cross-tricuspid differential pressure ≥ 5 mmHg;
  4. Previous tricuspid valve surgery or transcatheter therapy;
  5. Echocardiography suggested intracardiac thrombus, tumor or mass, or femoral vein and inferior vena cava implants or thrombus;
  6. TTE and TEE are unable to evaluate tricuspid valve anatomy; Participated in any drug and/or medical device clinical trials within 1 month prior to the trial; ……

28. The researchers do not consider it appropriate to be enrolled in the study.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
236 participants (estimated)

Study arms

  • Experimental
    Randomized - Device Group

    The experimental group is allocated to use a novel tricuspid valve repair system for edge-to-edge repair manufactured by Hangzhou Valgen Medtech Co., Ltd. and will continue to be managed on medical therapy, per physician discretion

    Device: DragonFly-T Transcatheter Tricuspid Valve Repair System

  • Active comparator
    Randomized - Control Group

    Subjects will continue to be managed on medical therapy, per physician discretion

    Drug: Medical therapy

Interventions

  • DeviceDragonFly-T Transcatheter Tricuspid Valve Repair System

    To conduct edge-to-edge repair with DragonFly-T System under the guidance of transesophageal echocardiography.

  • DrugMedical therapy

    Subjects will continue to be managed on medical therapy, per physician discretion

06

What researchers measure

Primary outcomes

  1. Hierarchical Composite of All-cause Death or Tricuspid Valve Intervention, Heart Failure Hospitalizations, and KCCQ Improvement

    Time frame: 12 months

Secondary outcomes

  1. Tricuspid regurgitation severity

    Percentage of patients with tricuspid regurgitation of 2+ or less.

    Time frame: 30 days, 6 months, and 12 months

  2. Change in 6 minutes walk test distance

    Improvement in 6 Minute Walk Test distance

    Time frame: 30 days, 6 months, and 12 months

  3. Quality of life improvement

    Improvement in quality of life (QoL) , as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ).

    Time frame: 30 days, 6 months, and 12 months

  4. Acute procedural success

    Time frame: Immediately after procedure, Discharge: The day after the patient's exit from the cardiac catheterization laboratory

  5. Acute device success

    Time frame: Immediately after procedure

  6. Incidence of major adverse events (MAEs)

    Time frame: 30 days

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Aug 2028, 47 months after the start.

Of 55 industry-sponsored interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's planned 47 months is above that.

Counting every sponsor, half of 86 studies reached it within 38 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2022
First posted
Sep 27, 2022
StartActual
Sep 3, 2024
Primary completionEst.
Aug 15, 2028
CompletionEst.
Aug 15, 2032
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05556460
Lead sponsor
Hangzhou Valgen Medtech Co., Ltd
Responsible party
Sponsor
First posted
Sep 27, 2022
Start date
Sep 3, 2024
Primary completion
Aug 15, 2028 (estimated)
Completion
Aug 15, 2032 (estimated)
Last update
Jun 12, 2026

Study contacts

Bo Liu
Contact
bo.liu@valgenmed.com
+8613001980902
Shuangjie Li
Contact
shuangjie.li@valgenmed.com
+8617756106609
Jian'an Wang, MD, PH.D
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion